Perrigo's 3.1% Sales Drop Hid Share Gains-Now the Market Wants Proof

Q2 improved the story, but not enough to reset the market's view

Perrigo's quarter reduced the immediate panic without fully rebuilding confidence. The company still delivered a 3.1% core net sales decline, core organic net sales fell 3.5%, and core adjusted gross margin dropped 150 basis points. That is the core credibility gap. Investors are no longer debating whether the backdrop is weak; they want evidence the business is stabilizing beneath the noise.

The quarter had positives, but the broader engine still looked fragile

The encouraging signals were real. Infant Formula net sales grew 23%, while US store brand OTC volumes growing 1.5% plus European key brands growing 3.3% showed some underlying demand resilience. But the broader picture remained mixed: Self-Care operating income declined 16.2% and Specialty Care operating income decreased about 28%. Bulls can read that as progress inside a difficult quarter. Bears will say incremental improvement is not the same as durable growth.

The stock still reflects that hesitation. Shares opened at $10.76, roughly half of the $26.99 12-month high, even with a 10.8% dividend yield. After the last earnings release, the stock drifted -16.1% lower over 69 days. The yield keeps investors watching. It does not settle the debate.

Share gains and service levels are management's best counterargument

That credibility gap matters because investors have heard about temporary pressure before. The real question now is whether the business is being rebuilt from the shelf upward, not just defended from the income statement down.

Better service levels matter more than the headline sales number

Management's clearest rebuttal is not the top-line decline. It is the evidence that retailers may be getting more comfortable with the supply chain again. Perrigo says U.S. service levels improved by 1,600 basis points to 91%, which should support deeper retailer relationships. That matters because a weak sales quarter can reflect buyer caution or destocking, not just soft consumer demand.

Just as important, Perrigo reports market share gains in U.S. store-brand OTC and key European brands. Management said that translated into 50 basis points of share growth in both. In a soft category, that matters: it suggests Perrigo is taking share from slower competitors, not just losing less than the field.

Bulls are looking past noisy unit sales to underlying consumption

Investors saw another sales decline and anchored on it. But management's argument is that the order stream has been noisy while underlying consumption is stabilizing. Perrigo said U.S. OTC volumes turned positive in July, which could signal a normalization in demand. It also pointed to retailer destocking in Europe as part of the sales pressure. If that reading is right, the next quarter could improve without a dramatic demand rebound-just with fewer distortions.

Portfolio simplification is being used as a confidence tool

Perrigo is also trying to simplify the story. It streamlined portfolio through completion of Dermacosmetics divestiture and is continuing strategic reviews of Infant Formula and Oral Care. Management reaffirmed its full-year 2026 outlook and emphasized stronger second-half performance.

Bears will argue that portfolio actions can obscure weakness. That is fair. But in a turnaround, early operating improvements matter because they are harder to fake than a clean sales print.

Why bears still think the setup is too expensive for a rerating

That is why Perrigo still sits in deep-value territory: the market will keep offering a turnaround multiple only if the numbers stop looking temporary.

Margin compression is still the problem

A turnaround is not enough if it is just "less bad." The operating model also has to start rebuilding the margin engine. Perrigo still reported a 3.1% core net sales decline, while core adjusted gross margin fell 150 basis points to 37% and core adjusted operating margin decreased 160 basis points to 13%.

That gap between soft revenue and tighter spreads is what keeps bears engaged. It suggests the business is dealing with pressure not only in the category backdrop, but through the income statement.

Segment results still argue against calling a turnaround too early

The segment picture matters because it shows where the damage sits. Self-Care operating income declined 16.2%, and Specialty Care operating income decreased about 28%. Those are the company's core operating businesses.

Bulls can point to Infant Formula net sales grew 23% and argue the quarter was mixed. But that is exactly why the stock remains controversial. One stronger unit does not erase the fact that the broader portfolio still shrank and became less profitable.

Debt limits the rerating, even if it does not create an immediate crisis

The balance sheet does not signal an imminent breakdown, but it does cap optimism. Perrigo ended the quarter with $400 million in cash and cash equivalents against $3.3 billion of total debt. That is manageable, especially after the divestiture proceeds were mainly applied to debt reduction. It is not, however, a position that naturally commands a growth multiple before more evidence arrives.

Add the June 8 leadership transition, with Albert Manzone named interim president and CEO, and the company still has an execution overhang. That is why the next print matters: investors need proof that the declines are narrowing across the model, not just in isolated parts of it.

What would make Perrigo a real turnaround trade instead of a dividend play

After the credibility gap and balance-sheet burden already priced in, Perrigo likely has to earn a rerating through earnings quality, not just yield. The current hinge is management's FY 2026 EPS guide of $2.25 to $2.55 against a $2.11 analyst consensus, while revenue guidance of $4.0 billion to $4.2 billion remains broadly in line with estimates. With a 10.8% yield, the market is still being paid to wait.

What the market needs to see next

The cleanest path is not a flashy revenue beat. It is evidence that the second half can deliver the expected earnings mix and that the operating story is becoming more durable. One accounting lever exists: Perrigo expects its 2026 effective tax rate to move from about 20% to about 18%. That helps, but it does not fix a weak operating trend on its own.

The more important shift would be for investors to move from fearing another retailer destocking in Europe hit to accepting that U.S. OTC volumes turned positive in July and that the business continues to post share gains.

What would invalidate the bearish view

If Perrigo fails to hold its full-year 2026 outlook, the stock probably remains a high-yield repair story rather than a true turnaround. If it does hold that outlook while sales deceleration slows and share gains persist, the market may start paying less attention to the dividend and more attention to earnings quality.